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Abstract: Objectives: Disorders of consciousness (DoC)—that is, unresponsive wakefulness syndrome/
vegetative state and minimally conscious state—are debilitating conditions for which no reliable
markers of consciousness recovery have yet been identified. Evidence points to the GABAergic system
being altered in DoC, making it a potential target as such a marker. Experimental design: In our prelim-
inary study, we used [11C]Flumazenil positron emission tomography to establish global GABAA recep-
tor binding potential values and the local-to-global (LTG) ratio of these for specific regions. These
values were then compared between DoC patients and healthy controls. In addition, they were corre-
lated with behavioral improvements for the patients between the time of scanning and 3 months
later. Functional magnetic resonance imaging resting-state functional connectivity was also calculated
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and the same comparisons made. Principal observations: lobal GABAA receptor binding was reduced in
DoC, as was the LTG ratio in specifically the supragenual anterior cingulate. Both of these measures
correlated with behavioral improvement after 3 months. In contrast to these measures of GABAA
receptor binding, functional connectivity did not correlate with behavioral improvement. Conclusions:
Our preliminary findings point toward GABAA receptor binding being a marker of consciousness
recovery in DoC. Hum Brain Mapp 00:000–000, 2015. VC 2015 Wiley Periodicals, Inc.
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INTRODUCTION
Unresponsive wakefulness syndrome (UWS; formerly
known as vegetative state) and minimally conscious state
(MCS) are debilitating neurological conditions character-
ized as disorders of consciousness (DoC). For patients
with DoC, early prognosis and therapy are crucial but
markers of recovery are presently lacking.
A number of lines of evidence suggest that the GABAer-
gic system could be a possible target for identifying such
markers. First, GABAergic substances such as Zolpidem, a
GABAA receptor agonist [Salva and Costa, 1995], appear to
be therapeutically efficacious in a subset of UWS and MCS
patients [Chatelle et al., 2014; Ciurleo et al., 2013; Clauss,
2011; Pistoia et al., 2010; Rodriguez-Rojas et al., 2013; Thon-
nard et al., 2014]. Second, an early positron emission
tomography (PET) study showed reductions in GABAA
receptors across the whole brain in nine patients with UWS
[Rudolf et al., 2000]. Unfortunately, this study did not
address specific regional deficits or recovery prognosis
[Laureys et al., 2000] and has not been followed up in any
subsequent investigations of GABAA receptors in DoC.
Recent studies have identified altered resting-state func-
tional magnetic resonance imaging (fMRI) activity in vari-
ous brain networks in patients with DoC, including the
salience network (SN), the default-mode network (DMN),
and the executive-control network (ECN) [Crone et al.,
2013; Demertzi et al., 2014; Qin et al., 2010; Thonnard
et al., 2013]. These networks, therefore, represent plausible
targets to focus any investigation of GABAA receptors on.
The SN may be of particular interest as fMRI activity lev-
els in a subcomponent of that network—the supragenual
anterior cingulate cortex (SACC)—induced by the presen-
tation of the patient’s name predicted clinical outcomes in
DoC [Qin et al., 2010]. In addition, Zolpidem administra-
tion was seen to increase activity within the ACC (and
orbitofrontal cortices), with concurrent transient improve-
ments in motor and cognitive performance in one patient
with akinetic mutism [Brefel-Courbon et al., 2007]. Zolpi-
dem administration has also been shown to increase
metabolism (as measured with [18F]flurodeoxyglucose
PET) in the mesiofrontal and dorsolateral prefrontal
cortices in three MCS patients [Chatelle et al., 2014]. All
three patients recovered functional communication after
Zolpidem administration, highlighting the potential of the
GABAergic system as a prognostic marker.
Given the potential importance of GABAergic changes
in DoC, one might hypothesize that measures of GABAA
receptors in the brain, and in particular in the ACC, can
predict recovery in DoC. To test this, we measured
GABAA receptor binding using [
11C]flumazenil PET, along
with resting-state fMRI. Although the available sample
size (n5 12 UWS and MCS) makes this study preliminary,
this multimodal approach is unique in DoC patients.
METHODS
Participants
Seventeen patients with DoC (11 UWS and 6 MCS) were
recruited. None were taking benzodiazepines at the time
of scanning, nor in the 3 months prior [Guadagno et al.,
2008]. Five patients (four UWS, one MCS) who required
sputum aspiration during the PET scan were excluded
from the analysis, leaving 12 DoC patients (seven UWS,
five MCS; four female; mean age5 45.6 years [63.3 SD];
age range5 23–61 years; time post injury range5 36–233
days; see Table I for patient details).
Diagnosis of UWS or MCS was made according to the
Coma Recovery Scale-Revised (CSR-R) [Giacino et al.,
2004] by an experienced physician (XW) who was not
involved in the analysis of the data. The CRS-R comprises
six subscales addressing auditory, visual, motor, oromo-
tor/verbal, communication, and arousal components,
reflecting the level of consciousness in the patient’s behav-
ior. Patients were assessed on the day before the PET ses-
sion and reassessed immediately prior to the PET scan
(T0). Importantly, the two assessments showed consistent
results for all patients. All patients were then reassessed 3
months after PET scanning (T1). This reassessment was
based on CRS-R scores from two separate examinations
within 1 week of each other (giving consistent scores for
all patients). The difference between CSR-R scores at T1
and T0 was taken as a measure of behavioral change for
the patients (i.e., T1 minus T0, where a positive score rep-
resents a behavioral improvement). Three patients who
showed behavioral improvements at T1 were rescanned;
however, the data from only one of these patients were
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usable as the other two patients felt discomfort in the
scanner and so could not complete the data acquisition.
Nine healthy volunteers participated in the study (four
female; mean age5 35.6 years [64.06 SD]; age range5 23–
55 years). There was no age difference between patients
and healthy controls (HC) (P5 0.07). None of the healthy
participants had a history of neurological or psychiatric
disorders or were taking medication. Two of these HC
were rescanned 3 months after their initial one (i.e., at T1).
Written informed consent was obtained from the healthy
participants and the legal representatives of the patients.
The study was approved by the Ethics Committees of the
Shanghai Huashan Hospital, Fudan University, Shanghai,
China.
GABAA Receptor Binding Potentials
PET imaging with radiolabeled flumazenil (FMZ), a ben-
zodiazepine antagonist that binds at the GABAA receptor
benzodiazepine site, has been widely used to measure
GABAA receptor density in vivo in humans [Frey et al.,
1991]. Whole-brain [11C]FMZ data was obtained using a
Siemens Biograph 64 positron emission tomography-com-
puted tomography (PET/CT). Head movement was mini-
mized with a head-restraining adhesive band. A CT scan
was acquired for attenuation correction, followed by an
intravenous tracer injection (over 60 s) of 380.3 MBq
(670.4 SD) of [11C]FMZ for HC and 386.0 MBq (670.0 SD)
of [11C]FMZ for patients. Doses did not differ between
patients and healthy subjects (independent two-sample t-
test, t5 1.86, P5 0.85). Participants were instructed to close
their eyes and remain awake during scanning. To ensure
that healthy participants remained awake during scanning,
they were asked to raise their hand every 10 min. Similar
prompts were given to patients, as has been done in previ-
ous studies [Demertzi et al., 2014; Vanhaudenhuyse et al.,
2010].
Three-dimensional (3D) list-mode data were acquired
for a period of 60 min and then binned into a series of 26
frames consisting of six 30-s frames followed by seven 60-
s, five 120-s, and eight 300-s frames [Salmi et al., 2008]. A
linear 3D filtered backprojection (3D-FBP) was preferred
for the modeling analysis of [11C]FMZ kinetics [van Vel-
den et al., 2009] with full accounting for scatter, random
TABLE I. Patient clinical information
Time since brain
PET scanning (T0) 3 months later (T1)
Patient Age/sex injury (days) Cause Lesions on MRI CRS-R Diagnosis CRS-R Diagnosis
MCS-1 36/M 38 TBI Bilateral frontal cortex 7 MCS 23 EMCS
MCS-2 51/M 229 SIH Brain stem and left basal ganglia,
left thalamus
9 MCS 9 MCS
MCS-3 54/M 111 TBI Bilateral temporal cortex and
bilateral frontal cortex, brain
stem
10 MCS 10 MCS
MCS-4 50/M 64 TBI Bilateral temporal cortex, left
occipital cortex, left basal
ganglia, left parietal cortex,
right thalamus, and brain stem
6 MCS 14 MCS
MCS-5 42/M 36 TBI Bilateral frontal cortex 7 MCS 23 EMCS
UWS-1 61/F 225 TBI Bilateral frontal and temporal
cortex, brain stem
6 UWS 6 UWS
UWS-2 58/M 194 TBI Bilateral frontal and temporal
cortex, right occipital cortex,
brain stem
4 UWS 4 UWS
UWS-3 37/M 47 TBI Bilateral frontal cortex, right
temporal and occipital cortex,
brain stem
5 UWS 5 UWS
UWS-4 23/F 233 TBI Left thalamus and brain stem 6 UWS 6 UWS
UWS-5 58/F 98 SIH Bilateral frontal and temporal
cortex, right thalamus and
brain stem
6 UWS – –
UWS-6 43/F 47 TBI Right temporal cortex and right
thalamus, brain stem
5 UWS 23 EMCS
UWS-7 35/M 115 TBI Right temporal and occipital
cortex, bilateral frontal cortex,
brain stem
7 UWS 21 EMCS
Note: EMCS5 emergence from minimally conscious state. “–” denotes unavailable information. TBI5 traumatic brain injury; SIH5 -
spontaneous intracerebral haemorrhage.
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coincidences, attenuation, decay dead-time correction, and
frame-based motion correction [Costes et al., 2009]. The in-
plane reconstructed resolution was 6-mm full-width at
half-maximum. The images used had a voxel size of 1.22
3 1.22 3 1.22 mm3 (256 3 256 3 207 voxels). We used a
subset from 10 to 60 min to calculate the binding potential
(BPND) according to the Logan plot method [Logan et al.,
1996]. The bilateral cerebellar white matter was used as
the reference as it generally has less damage than other
brain regions in DoC patients [Qin et al., 2012; Rudolf
et al., 2000] (see Supporting Information Fig. 1 for patient
cerebellar structural images). To define this reference
region, each person’s T1-weighted 3D anatomical MRI
image (see MRI Data Acquisition and Processing for
details) was segmented using the FAST tool from FSL to
give a white matter map and then aligned to their binding
potential image. The white matter maps were masked
with the cerebellar mask from the Harvard Oxford atlas
(http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/Atlases), thresholded
at 0.9 (from a range of 0 to 1), and binarized. The resulting
cerebellar white matter mask was then eroded by one
voxel to generate the final individual reference region.
Regions of Interest
Using the AFNI template (TT_desai_dk_mpm) [Desikan
et al., 2006], we defined regions of interest (ROIs) corre-
sponding to the functional networks identified in previous
studies as showing altered activity in DoC [Crone et al.,
2013; Demertzi et al., 2014; Qin et al., 2010; Thonnard
et al., 2013]. These were the SN, the DMN, the ECN, and
the auditory network (AN). The SN ROI was composed of
the SACC and anterior insula (AI); the DMN of the poste-
rior cingulate cortex (PCC), perigenual anterior cingulate
cortex (PACC), and bilateral temperoparietal junction
(TPJ); and the ECN of the bilateral dorsolateral prefrontal
cortex (DLPFC), bilateral inferior parietal lobe (IPL), and
precuneus (PreCu). The AN included the bilateral auditory
cortex. As the AFNI template does not include a separate
AI mask, we created the insula ROI by combining the ven-
tral and dorsal AI regions identified by Deen et al. [2011].
To obtain the individual ROIs for each participant, the
BPND map of each participant (HC and patients) was nor-
malized to a standard T1-weighted template, as described
previously [Duncan et al., 2013]. The inverse of these
normalization parameters were then used to warp the rele-
vant ROIs from the AFNI template onto the nonnormal-
ized individual BPND maps for healthy and patient groups
[Qin et al., 2010].
Calculating BPND in Gray Matter
As the GABAA receptor is predominantly located in the
gray rather than white matter [Heiss and Herholz, 2006],
and because BPND is known to correlate with gray matter
density [Duncan et al., 2013], it is necessary to limit the
ROIs to gray matter only. Were the whole ROI (including
both gray and white matter) to be used, any results could
be attributed to differences in the volume of gray matter
within the particular region between participants rather
than differences in GABAA receptors per se. We, therefore,
calculated BPND in gray matter alone as follows: MRI ana-
tomical images were segmented to give gray matter maps.
These were thresholded at 0.5 to create a mask of high-
probability gray matter voxels and converted into PET
space. To remove additional nontissue voxels, we also
thresholded the BPND maps at 0.5 and applied this mask
to the gray matter mask (see Supporting Information Fig.
1 for an example mask). Network ROIs in PET space cre-
ated previously were then restricted according to these
gray matter masks. Finally, the mean GABAA receptor
BPND within each ROI and within the gray matter as a
whole was calculated. To correct for unspecific gray matter
volume effects, the mean GABAA BPND for each region
was divided by the mean gray matter proportion of that
region [Qin et al., 2012]. This was done for each network
ROI and for the total gray matter region.
Statistical Analysis for PET
For whole-brain BPND values difference between DoC
and HC, the effect of age and FMZ dose were removed
from the whole-brain BPND values using linear regression.
The resulting residuals for the whole-brain BPND values
were then compared between DoC patients and HC
through a Mann–Whitney U test. For the relationship
between whole-brain BPND and CRS-R scores, the effect of
participant age, the dose of FMZ, and the length of time
since the patient’s injury were removed from the whole-
brain BPND values and CRS-R scores through linear regres-
sion. The Spearman’s correlations between the resulting
residuals for the global BPND values and both the CRS-R
scores at T0 and the behavioral change (i.e., CRS-R T1-T0)
were then calculated. Finally, as the CRS-R is not a purely
quantitative measure but also requires particular patterns
of scoring for different diagnoses, we further tested the
association between BPND and behavioral improvement by
first classifying a patient as improved or not from whether
their CRS-R score was higher at T1 than at T0. They were
then classified as having a global BPND value within or
outwith two standard deviations of the mean for healthy
participants. The correlation between these classifications
was then established through a Fisher’s exact test. This
classification approach has the additional advantage of
potentially providing information that is directly clinically
relevant.
Having investigated whole-brain BPND values, we then
focused on these values for particular networks. For this,
the BPND local-to-global (LTG) ratio was calculated for each
network and this value used in the subsequent calculations
[Qin et al., 2012]. This value represents the mean BPND in
each network divided by the average BPND of the whole
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brain, allowing us to measure potentially differential
changes in specific regions relative to the global value and
so increase specificity by eliminating global effects. This
division may also eliminate the potential effect of age, FMZ
dose, and length of time since injury on GABAA BPDN val-
ues [Yamauchi et al., 2005]. Differences between patient
and control LTG ratios were tested through Mann–Whitney
U tests. Bonferroni correction for the four networks was
done in each of these comparisons (SN, DMN, ECN, and
AN) (P< 0.05; P< 0.0125 uncorrected).
Finally, following the network level analysis, we investi-
gated the various constitutive brain regions within any of
the networks that showed a difference in FMZ BPND LTG
ratio between patients and controls. We repeated the same
analysis in each subregion as was done for the network as
a whole. In addition, Spearman correlations between net-
work LTG ratios and CRS-R scores at T0 and the behav-
ioral change (T1-T0) were also calculated. Within the
specific network, Bonferroni correction was done based on
the number of brain regions constituting it.
MRI Data Acquisition and Processing
Of the 12 patients with usable PET data, 10 also had fMRI
data available. All HC had usable fMRI data. MR images
were acquired on a Siemens 3 Tesla scanner. Functional
images were acquired using a T2*-weighted echo-planar
imaging sequence (repetition time/echo time/h5 2,000
ms/35 ms/908, field of view5 256 mm, matrix5 64 3 64,
slice thickness5 4 mm, gap5 0 mm, 33 slices, 200 volumes).
A T1-weighted high-resolution 3D whole-brain image was
also obtained (repetition time5 2300 ms, echo time5 2.98
ms, Matrix5 256 3 256, slice thickness5 1 mm). fMRI
imaging was done randomly either before or after the PET
scan (mean duration between scans5 8.1 days6 8.9 SD).
The diagnoses remained the same for all patients during
both fMRI and PET scanning. All the participants (HC and
patients) were instructed to close their eyes and remain
awake during scanning. Unfortunately, due to their condi-
tion, it was not possible to entirely ensure wakefulness in
the patients [Demertzi et al., 2014].
The data were processed using the AFNI and FSL soft-
ware packages. The first two volumes were discarded. The
data then underwent a preprocessing procedure that
included slice-timing correction, two- and three-
dimensional head-motion corrections, masking for the
removal of the skull, and spatial smoothing using a 6-mm
full-width at half-maximum kernel. Time-series were then
normalized by computing the ratio of the signal in each
voxel and each time point to the mean across all time
points, multiplied by 100. The estimated head motion and
the mean time-series from the white matter and the cere-
brospinal fluid (where these regions were defined using
thresholds of 0.99 for each tissue type) were regressed out
of the data [Saad et al., 2012]. The data were band-pass
filtered, reserving signals between 0.01 and 0.08 Hz [Song
et al., 2011].
As minor group differences in head motion can cause
spurious differences in imaging measures between them
[Power et al., 2012; Van Dijk et al., 2012], a rigorous
approach to head-motion correction was adopted. Motion
was quantified as the absolute Euclidean distance moved
from the head position in the prior time point, as calcu-
lated from the six rigid-body motion parameters. Where
there was movement of more than 0.5 mm between time
points, the relevant volume, plus the preceding and subse-
quent volumes, was removed from the dataset [Huang
et al., 2013]. To obtain reliable functional connectivity val-
ues, participants with less than 3 min of data remaining
following this procedure were excluded [Yan et al., 2013].
This resulted in the exclusion of three patients (from 10).
We explored the resting-state functional connectivity
between the different regions that compose the SN (the AI
and the SACC). This network was chosen for the analysis
as it was the only one that shows a difference in FMZ
BPND LTG ratio between patients and controls. Consider-
ing the similar time course in the corresponding regions
between the two hemispheres, and to reduce physiological
and scanner noise, we collapsed the time courses from the
bilateral AI. Pearson’s correlation coefficient between the
time-series of AI and SACC was calculated and converted
to normally distributed Z-values using Fisher’s Z transfor-
mation. These Z-values were compared between patients
and controls using a Mann–Whitney U test. Finally, we
calculated the Spearman correlation between functional
connectivity and CRS-R scores at T0, as well as the behav-
ioral change (CRS-R T1 –T0). The significance level was set
at P< 0.05.
RESULTS
Behavioral and Clinical Data
Five patients showed clear behavioral improvements
between T0 and T1 (MCS 1, 4, 5 and UWS 6, 7). MCS 1, 5
and UWS 6, 7 could perform verbal communication 3
months after the initial assessment (Table I, plus Support-
ing Information Tables I and II). Although MCS 4 was
unable to verbally communicate in a stable fashion, they
were able to say intelligible words, pursue a visual stimu-
lus, and localize noxious stimulation at T1 (they was
unable to do these at T0). The remaining patients did not
show any behavioral changes between T0 and T1.
Whole-Brain GABAA Receptor BPND
Mean whole-brain GABAA receptor BPND values were
significantly lower (37% reduction) in DoC patients than
in HC (P5 0.001) (Fig. 1B). There was a positive correla-
tion between GABAA receptor BPND and behavioral
change (CRS-R T1-T0) (rho5 0.62, 95% confidence interval
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r 5 r
[C.I.]5 0.012 0.989, P5 0.043), but no correlation with
CRS-R scores at T0 (Fig. 1 and Supporting Information
Fig. 2)
Testing the relationship between behavioral improve-
ment (classed according to whether CRS-R T1>T0) and
BPND (classed according to whether BPND values lie within
Figure 1.
Global GABAA receptor BPND. (A) GABAA receptor BPND
maps from all the patients with DoC and one HC. (B) Global
GABAA receptor BPND values (mean6 SE) for DoC patients
and HC. * denotes a significant difference (P< 0.05). Spearman
correlation between global GABAA receptor BPND values and
CRS-R scores at (C) the time of scanning (T0) and (D) CRS-R
difference between T1 and T0 (T1-T0). Note that these graphs
show residuals after confounding factors (age, FMZ dose, and
time since injury) have been regressed out from both global
GABAA receptor BPND values and CRS-R scores. (E) Scatter
plot of global GABAA BPND values and the difference in CRS-R
scores between T0 and T1. The blue shaded area represents
the range of mean6 2*SD of the HC. Note that the bar repre-
sents the difference between T0 and T1 and is not shown in the
patients who have no difference. The label of either UWS and
MCS represents the diagnosis at T0. [Color figure can be
viewed in the online issue, which is available at wileyonline
library.com.]
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2 SD of HC mean), a positive correlation was observed
(Fisher’s exact test, P5 0.015) (Fig. 1E). All patients who
did not improve between T0 and T1 showed lower
GABAA receptor BPND than those who had an improve-
ment in their level of consciousness.
Network GABAA Receptor BPND
Absolute GABAA receptor BPND in each of the networks
studied (SN, DMN, ECN, and AN) was lower in patients
than in HC (Supporting Information Fig. 3). Taking this
global reduction into account through LTG ratios, there
was a relative reduction in GABAA receptor BPND values
between patients and HC in the SN specifically (P5 0.024
corrected; P5 0.006 uncorrected) (Fig. 2). There was no
reduction in LTG ratios in the other networks studied.
Within the patient group, there was no different in LTG
ratios between UWS and MCS patients (Supporting Infor-
mation Fig. 4 and 5).
GABAA Receptor BPND in the SN
With only the SN showing reduced LTG ratios, we
investigated this network further by dividing it into its
constituent regions—the SACC and the AI. BPND LTG
ratios were significantly reduced in the SACC in patients
with DoC when compared with HC (P5 0.004 corrected;
P5 0.002 uncorrected), as were LTG ratios in the AI
(P5 0.036 corrected; P5 0.018 uncorrected) (Fig. 3B).
We then tested the correlation between LTG ratios and
behavioral change (CRS-R T1 minus T0) in each region.
The LTG in the SACC was significantly correlated with
behavioral change (rho5 0.81, 95% C.I.5 0.482 0.95,
P5 0.004 corrected, P5 0.002 uncorrected) (Fig. 3C), while
no correlation was seen in the AI. However, the relation-
ship between LTG ratio in the SACC (whether LTG ratio
lie within 2 SD of HC mean) and behavioral improvement
classification (CRS-R T1>T0) was not significant (Fisher’s
test, P5 0.08) (Fig. 3D).
To establish the specificity of the SACC, we also investi-
gated other areas of the cingulate cortex (Supporting Infor-
mation Fig. 6). A reduction in LTG ratios in DoC patients
was additionally seen in the perigenual anterior cingulate
(PACC). There was no change in the mid-cingulate cortex
and the PCC. However, there was no correlation between
LTG ratios of the PACC and CRS-R scores at T0 or with
behavioral change (T1-T0).
BPND After Behavioral Improvement
UWS6 was scanned at both T0 and T1. Both their global
BPND and LTG ratio in the SACC were located within the
range of the HC at T1 (they were also in this range at T0).
Two HC also underwent a second scan 3 months after
their first. There were no differences in their global BPND
values between these times (Supporting Information
Fig. 7).
Figure 2.
LTG GABAA BPND ratios (mean6 SE) for networks studied in
DoC patients and HC. The upper panel shows the regions that
make up each network. * denotes a significant difference
(P< 0.05, corrected). AC5 auditory cortex, AI5 anterior insula,
DLPFC5 dorsolateral prefrontal cortex, IPL5 inferior parietal
lobe, PACC5 perigenual anterior cingulate cortex, PCC5 pos-
terior cingulate cortex, PreCu5 precuneus, SACC5 supragenual
anterior cingulate cortex, TPJ5 temperoparietal junction. [Color
figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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Functional Connectivity in the SN
Functional connectivity between the SACC and AI (the
subregions of the SN) was reduced in patients with DoC,
as compared with HC (P5 0.016) (Fig. 4). However, unlike
with GABAA receptor BPND, functional connectivity did
not correlate with patients’ CRS-R scores at T0, nor with
their behavioral change (T1-T0)
Although outwith the focus of our analysis, for com-
pleteness, we also looked at functional connectivity in the
other networks. Functional connectivity was reduced in
each of the DMN, ECN, and AN in DoC patients. Subdi-
viding these networks into their constituent ROIs, in the
DMN, functional connectivity was reduced between the
PACC and PCC; while in the ECN, functional connectivity
was reduced between the DLPFC and PreCu only (Sup-
porting Information Fig. 8).
DISCUSSION
Our preliminary study reports major GABAA receptor
deficits in the whole brain, in the SACC in particular, and
in DoC. These GABAergic alterations can predict recovery
after 3 months. The potentially special role of the SACC
was further supported by alterations in resting-state func-
tional connectivity, as measured with fMRI, in the same
patients. Although preliminary, our results demonstrate
for the first time that GABAA receptor BPND can be linked
to outcomes in DoC. Our findings may bear important
implications for the understanding of altered GABAergic
mechanisms in DoC and point toward use of FMZ PET as
a prognostic marker in UWS and MCS.
Global Deficits in GABAA Receptors and
GABAergic Therapy
Our study replicated earlier findings of reduced whole-
brain GABAA receptor binding in UWS [Rudolf et al.,
2000] and extended them by providing a link to outcomes.
Previous studies suggested that GABAA receptor changes
could reflect irreversible neuronal damage [Heiss, 2012].
Figure 3.
LTG BPND ratio in SN. (A) Brain regions forming the SN.
SACC5 supragenual anterior cingulate cortex, AI5 anterior
insula. (B) The LTG BPND ratio (mean6 SE) for DoC patients
and HC in the SACC and AI. * denotes a significant difference
(P< 0.05, corrected). (C) Spearman correlation between the
behavioral change (CSR-R T1-T0) and LTG ratio in the SACC.
(D) Scatter plot of LTG GABAA BPND ratios in the SACC and
the difference in CRS-R scores between T0 and T1. The blue
shaded area represents the range of mean6 2*SD of the HC.
Note that the bar represents the difference between T0 and T1
and is not shown in the patients who have no difference. The
label of either UWS and MCS represents the diagnosis at T0.
[Color figure can be viewed in the online issue, which is avail-
able at wileyonlinelibrary.com.]
Figure 4.
Functional connectivity (FC) (Mean6 SE) between SACC and
AI. Pearson’s r-values were converted to Fisher’s Z-values. *
denotes P< 0.05. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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This may provide one potential interpretation to the prog-
nostic value of whole-brain GABAA receptor BPND. This is
supported by the data from the patient scanned at both T0
and T1, where there is no difference in BPND before and
after recovery of consciousness.
GABAergic drugs such as Zolpidem have been shown
to restore consciousness in some DoC patients [Ciurleo
et al., 2013; Clauss, 2010; Clauss, 2011; Pistoia et al., 2010].
The mechanism of this effect is unknown but may be
related to the hypersensitive state of GABA receptors in
neurodormant cells [Clauss and Nel, 2006]. It is hypothe-
sized that after brain injury GABA receptors become
hypersensitive so that decreased GABA can suppress cel-
lular metabolism and maintain a dormant state. With the
introduction of Zolpidem, GABA receptor function may be
returned to normal, ceasing the dormant state. Based on
our findings, one would predict that the subset of patients
who are reactive to Zolpidem [Whyte et al., 2014] might
show particularly high degrees of GABAA receptor bind-
ing when compared with those that do not [Ciurleo et al.,
2013; Du et al., 2014; Singh et al., 2008].
SN and SACC in DoC
In addition to whole-brain changes, we also showed that
there is a reduction in the LTG ratio of GABAA receptor
BPND in the SN, specifically in the SACC. As with whole-
brain BPND, the SACC LTG ratio was correlated with
behavioral improvement after 3 months. The SN, and par-
ticularly the SACC, has previously been demonstrated to
be associated with consciousness [Crone et al., 2013;
Devinsky et al., 1995; Qin et al., 2010]. Moreover, the
“mesocircuit hypothesis” for the recovery of consciousness
claims a central role for the connection between thalamus
and anterior frontal cortex (especially the SACC) in recov-
ery of consciousness [Schiff, 2010]. Our results provide
support for this hypothesis by showing a particular rela-
tionship between SACC BPND and the recovery of
consciousness.
Functional connectivity between the SACC and the AI
was also reduced in patients with DoC. Unlike with SACC
BPND, however, the degree of connectivity was not corre-
lated with the level of consciousness at T1. This suggests
that there may be a dissociation in the role that SACC
GABAA receptor binding and functional connectivity play
in supporting consciousness. If we consider GABAA recep-
tor BPND to reflect neuronal integrity [Heiss, 2012], then,
this contrasts with functional connectivity, which instead
reflects neural activity synchronization between regions. In
DoC patients, the remaining tissue may suffer from a
major decrease in metabolism [Laureys and Schiff, 2012;
Northoff, 2014; Shulman et al., 2003]. Such a metabolic
decrease may put neurons into the aforementioned
“dormant state” which may in turn down-modulate func-
tional connectivity [Ciurleo et al., 2013; Du et al., 2014].
Besides the SN, previous studies have also shown
reduced functional connectivity within the DMN, ECN,
and AN in DoC patients when compared with HC
[Demertzi et al., 2014]. This is consistent with our findings
of significantly reduced functional connectivity (Support-
ing Information Fig. 8) and BPND in these networks (Sup-
porting Information Fig. 3). The reduction in BPND would
appear to reflect a generalized or global effect, as the dif-
ference between DoC patients and controls is lost follow-
ing normalization of the values (i.e., the calculation of the
LTG ratio). Such global GABAergic alterations may be
linked to the reductions in functional connectivity
observed across the networks. When considering the LTG
ratio, significant reductions in GABAA BPND remained
only in the SACC (and not in the other regions and net-
works). This suggests that GABAA BPND in the SACC is
reduced in a regionally specific manner not shared by the
rest of the brain. Importantly, it is this region that shows a
particular relevance for predicting the recovery of
consciousness.
Limitations and Future Directions
The modestly sized and clinically somewhat heterogene-
ous sample must be mentioned. Although the current data
must be considered preliminary, the results are consistent
with a prior study showing reduced GABAA receptor den-
sity in nine acute DoC patients [Rudolf et al., 2000]. Fur-
thermore, FMZ PET is a well-developed method that gives
stable and reliable results [Salmi et al., 2008]. However, it
is necessary to replicate our results in larger and more
homogeneous samples. A second limitation is that only
one patient could be scanned successfully after recovery.
This leaves open interesting questions as to how GABAA
BPND may change in line with behavioral improvement.
Similarly, the rescanning of patients who do not improve
would provide information as to whether irreversible
brain damage in these patients remains unchanged or gets
worse. Future studies may seek to include a brain-lesioned
group who retain full consciousness to act as a control for
the effect of focal brain injury itself. Moreover, it may be
advisable to investigate recovery over periods longer than
3 months. Finally, fluorodeoxyglucose (FDG) PET values
have previously been shown to be correlated with [11C]flu-
mazenil PET [Rudolf et al., 2002]. FDG is a more com-
monly used tracer in DoC patients [Stender et al., 2014]
and so it would be interesting to establish if this method
can be used in place of FMZ to make clinical outcome pre-
dictions by applying an analogous methodology to that
described here.
In conclusion, although preliminary, our study demon-
strates for the first time that GABAA receptor binding in
the whole brain, and in the SACC particularly, predicts
behavioral improvement in DoC. This complements recent
clinical reports of therapeutic efficacy of the GABAergic
drug Zolpidem in these patients.
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